ABSTRACT
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multi-organ damage with infiltration and sequestration of various immune cells
(1) . It is a connective tissue disease with evident formation of autoantibodies and immune complexes leads to activation of complement systems and subsequent inflammation (2-4) . SLE patients exhibit numerous aberrations in the immune system, comprising B cells, T cells, monocytes, and dendritic cells, resulting in B and T cell activation and consequent autoantibodies production against a large variety of autoantigens (5) . Angiogenesis and microvascular endothelial injury play a role in the pathogenesis of SLE (6) . Moreover, SLE is characterized by an inflammatory immune response mediated, in part, by cytokines and chemokines produced by antigen presenting cells (APC) and other immune cells, contributing for disease development and progression (7) . The exact etiology still remains unclear; however defective clearance of apoptotic material and/or aberrant apoptosis, in combination with susceptible genetic background have been suggested to be involved in SLE development and progression (8-10) . Fractalkine (Fkn) (CX3CL1) is the unique member of the CX3C chemokine subfamily because it is synthesized as a transmembrane molecule consisting of an extracellular N-terminal domain (residues 1-76), a mucin-like stalk (residues 77-317), a transmembrane α helix (residues 318-336) and a short cytoplasmic tail (residues 337-373) (11) . In contrast to other chemokines, it exists in two forms, each mediating distinct biological actions (11-13) . The membrane-anchored protein, which is primarily expressed on the inflamed endothelium, serves as an adhesion protein promoting the retention of monocytes and T cells in inflamed tissue. The soluble form resembles more a conventional chemokine and strongly induces chemotaxis (14) . Fkn is expressed at very low levels by resting endothelial cells but undergoes marked upregulation following stimulation of the cells by cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1ß (IL-1ß) (15) . Fractalkine/CX3CL1 expressed on inflamed endothelium may play a role as a vascular gateway for cytotoxic effector cells (CX3CR1-expressing cells) by rapidly capturing them from the blood and promoting migration into tissue (11) . Indeed, investigations by several groups, have implicated CX3CL1 in a variety of inflammatory disorders, including glomerulonephritis, RA, systemic sclerosis and SLE (16, 17) . The purpose of the current study was to determine the Fractalkine / CX3CL1 level in SLE patients and correlates that level with indices of disease activity and damage, trying to disclose its role in the pathogenesis of SLE.
MATERIALS & METHODS
Forty SLE patients (36 females and 4 males with mean age of 28 ±11.6 years) who were fulfilling the American College of Rheumatology (ACR) Classification Criteria for SLE (18) were recruited for the study. Mean disease duration was 9 ±5.5 years. For disease activity in our patients mean BILAG global score was 12 ± 4.8. SLE patients were classified into two groups, active and inactive according to the BILAG -Group 1 comprised 15 patients with active SLE (14 females and a male with mean age of 32 ±9.8 years was used to assess organ damage.
Laboratory tests:
Full blood count, ESR, CRP, and total hemolytic complement activity (CH50), immune complex (C1q). Auto-antibodies were screened at the base line visit and included each of the following: antinuclear antibody (ANA), anti-Ro, anti-La, antiphospholipid (IgM, IgG) anti-Sm, anti-RNP, and anti-dsDNA. ANA was measured using immunofluorescence; antibodies to dsDNA were measured by ELISA or Farr assay. Testing for extractable nuclear antigens (anti-Ro, anti-La, anti-Sm and anti-RNP) was done by ELISA followed by a confirmatory immunoblot. Seropositivity was defined as one or more positive assays for that particular antibody measured at any point during a patient's disease course. Clinical laboratory tests were performed according to standard hospital laboratory procedures. Soluble Fractalkine (sFkn) level was detected by ELISA Kits from R&D system, Minneapolis-MN, USA; Catalogue number DY365. Briefly, standards, samples and controls were pipetted into wells, pre-coated with monoclonal antibody specific for Fkn, any Fkn present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme linked polyclonal antibody specific for Fkn is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Fkn bound in the first step. The reaction stopped with the addition of stop solution and the microtiter plate was then read at 450 nm wave length. Thereafter, RNA was reversed transcribed from 2.5 µg total RNA according to the manufacturer's instructions, using random hexamers (Invitrogen). cDNA was used for realtime PCR with the help of StepOne™ real-time PCR system (Applied Biosystems, Foster City, CA, USA).
The sequences of oligonucleotide primers used in the PCR for detection of FKN / CX3CL1 expression levels, were as follows: for human Fkn 5-GCT-GAG-GAA-CCC-ATCCAT (sense), 5-GAG-GCT-CTG-GTA-GGT-GAA-CA (antisense); for GAPDH sense: 5′-GAAGATGGTGATGGGATTTC-3′ and anti-sense: 5′-GAAGGTGAAGGTCGGAGT-3′.
Cycling conditions were as follows: step 1, 15 minutes at 95°C; step 2, 20 seconds at 94°C; step 3, 20 seconds at 60°C; and step 4, 20 seconds at 72°C, with repeat from step 2 to step 4 for 45 cycles. Data from the reaction were collected and analyzed. The relative copy numbers of gene expression were quantitated using the comparative threshold cycle (ct) method. 
RESULTS
(1) Serum sFkn (CX3CL1) levels by ELISA:
SLE patients (n = 40) had significantly raised plasma levels of CX3CL1 (mean ± SD 444.8 ±120.7 pg/ml) compared with RA patients (n = 30) (210.7 ± 59.7 pg/ml; P <0.05) and healthy controls (n= 20) (2.4 ± 1.2 pg/ml; P < 0.05). Furthermore, patients with active disease (n= 15) had significantly raised CX3CL1 levels (532.8 ±180.7 pg/ml) compared with the patients in inactivity (n= 25) (322.3 ±110.7 pg/ml) (P <0.05), while there is a significant increase in sFkn levels in inactive SLE patients when compared to RA patients and control group (P <0.05). Table (1) and figures (1) and (2) illustrate these results. For the relationship between serum levels of sFkn (CX3CL1) and disease activity assessed by BILAG disease activity index and organ damage assessed by SLICC/ACR damage index and the related serologic parameters, the following results were obtained. Serum levels of sFkn were positively correlated with disease activity (r = 0.331, P<0.05), organ damage (r=0.349 P<0.05), antidsDNA antibody titers (r = 0.345, P<0.05), anti-Sm antibody titers (r=0.311, P<0.05), immune complex C1q levels (r=0.301, P <0.05), antiphospholipid (IgM, IgG, r = 0.321, 0.319 respectively, P<0.05 for each) , anti-RNP (r = 0.342 P <0.05), ESR level (r = 0.402 P <0.05). However, sFkn serum levels were negatively correlated with CH50 (r = 0.292, P < 0.05). Table 3 illustrates these results. 
DISCUSSION
In the current study, we show increased plasma levels of CX3CL1 either sFkn/CX3CL1 detected by ELISA or Fkn/CX3CL1 mRNA detected by PCR in SLE patients with particularly high levels of the ligand in those with active disease. This was shown after comparison of our SLE cohort with a group of disease RA controls, and normal healthy volunteers. Moreover, a positive correlation was detected between CX3CL1 and disease activity index by BILAG score and disease damage index by SLICC/ACR. Furthermore, a positive correlation was found also with laboratory immunological autoantibodies relating to disease activity like anti-dsDNA, anti-Sm, beside high ESR and immune complex (C1q). Of interest, other autoantibodies were found to have a positive correlation with CX3CL1 like anti-phospholipid (IgM, IgG), and anti RNP. Since these findings are unique, they need further work to declare the correlation between CX3CL1 like with other autoimmune rheumatological disorders linked to SLE, like mixed connective tissue disorder (for anti RNP) and antiphospholipid antibody syndrome (for anti-phospholipid antibodies).
A wide range of reports have published denoting levels of the chemokine fractalkine in patients with SLE. 
